New Molecular Entities Approved In 2010
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals as FDA enters the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year.
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.